Related Experiment Video
Updated: Mar 13, 2026
The Use of Trace Eyeblink Classical Conditioning to Assess Hippocampal Dysfunction in a Rat Model of Fetal Alcohol Spectrum Disorders
Published on: August 5, 2017
Fetal antiepileptic drug exposure and cognitive outcomes
Rebecca L Bromley1, Gus A Baker2
1Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Insights
Valproate exposure in utero is linked to poorer neurodevelopmental outcomes. Other antiepileptic drugs show mixed results, highlighting the need for more research on maternal and fetal risks.
Area of Science:
- Neurodevelopmental outcomes
- Pregnancy and Epilepsy
- Pharmacovigilance of Antiepileptic Drugs
Background:
- Valproate is a known human teratogen, necessitating a balance between maternal health and fetal safety.
- Increased research is crucial to understand risks associated with antiepileptic drug (AED) treatments during pregnancy.
- The need for evidence-based decision-making in managing epilepsy during pregnancy is paramount.
Purpose of the Study:
- To review and synthesize current literature on neurodevelopmental outcomes following prenatal exposure to various antiepileptic drugs (AEDs).
- To compare the neurodevelopmental effects of valproate, carbamazepine, and lamotrigine with control groups and other AEDs.
- To identify gaps in knowledge regarding AEDs and their long-term impact on child neurodevelopment.
Main Methods:
- A comprehensive literature review of published studies was conducted.
- Studies compared neurodevelopmental outcomes in children exposed in utero to AEDs versus control children.
- Analysis focused on outcomes associated with valproate, carbamazepine, lamotrigine, levetiracetam, and topiramate.
Main Results:
- In utero valproate exposure correlated with poorer neurodevelopmental outcomes compared to controls and other AEDs.
- Carbamazepine exposure showed no majority link to poorer early development, but long-term cognitive data is limited.
- Lamotrigine exposure suggests no difference in early development or IQ, but specific cognitive skills require further investigation.
- Evidence for levetiracetam and topiramate neurodevelopmental effects remains limited.
Conclusions:
- Current evidence on AEDs and neurodevelopmental outcomes is incomplete, hindering evidence-based clinical decisions.
- Further research is needed to provide women with confidence regarding the known risks and benefits of commonly used AEDs.
- Understanding children with neurodevelopmental difficulties post-AED exposure and effective interventions is a critical future research direction.
Purpose:
Data highlighting valproate as a human teratogen put in context the need to balance both maternal and fetal needs; maximising maternal health whilst minimising fetal risk. This led to increased research efforts to understand the associated risks with AED treatments.
Methods:
A review of currently published literature was undertaken.
Results:
In utero exposure to valproate was associated with a range of poorer neurodevelopmental outcomes when compared to control children and children exposed to other antiepileptic drugs (AEDs). Children exposed to carbamazepine were not found by the majority of studies to have poorer early development, although there is a lack of evidence regarding specific cognitive skills later in childhood and adolescence. Research regarding lamotrigine was limited to a small number of studies but suggests early global development or school aged IQ does not differ from control children, but less is known about specific cognitive skills. Evidence for the other AEDs including levetiracetam and topiramate were significantly limited.
Conclusions:
Despite an improvement in momentum the evidence remains incomplete for neurodevelopmental outcomes and this limits evidence-based decision making. Further efforts are required to enhance the treatment of women by giving them the confidence that both the risks and the benefits of commonly used AEDs are known. Future research should also seek to increase our understanding of the children who experience neurodevelopmental difficulties in the context of exposure in the womb to AEDs and what interventions may be successful in maximising the outcome of these children.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:07Teratogenicity
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...